caa a22 4500 397593139 CHVBK 20180308164944.0 cr unu---uuuuu 161202e199606 xx s 000 0 eng 10.1093/jac/37.suppl_C.93 doi (NATIONALLICENCE)oxford-10.1093/jac/37.suppl_C.93 Gris P. Department of Pneumology/Physiology, Clinique Cesar de Paepe, Brussels, and Hopital Civil de Jumet, 6040 Jumet, Belgium Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study [Elektronische Daten] [P. Gris] A 3-day regimen of azithromycin (500 mg once daily) and a 10-day regimen of co-amoxiclav (625 mg three times daily) were compared in a double-blind study of 67 patients with acute infectious exacerbations of chronic bronchitis (AIECBs, n = 54), acute bronchitis (n = 7), or pneumonia (n = 6). In patients treated with azithromycin, satisfactory clinical responses (cure or improvement) were seen in 24/28 (86%) patients with AIECBs, 2/4 (50%) with acute bronchitis and 2/2 (100%) with pneumonia. Responses were satisfactory in 24/26 (92%), 4/4 (100%) and 4/4 (100%) patients, respectively, receiving co-amoxiclav. Streptococcus pneumoniae and Haemophilus influenzae were the commonest pathogens isolated at baseline. At the end of treatment, baseline pathogens were eradicated in 9/10 microbiologically-as-sessable patients treated with azithromycin and in 10/10 treated with co-amoxiclav. Adverse events related or possibly related to treatment occurred in five patients in each treatment group; the majority of these events affected the gastrointestinal system. One patient in each treatment group discontinued therapy because of adverse events. The study, therefore, demonstrates that 500 mg azithromycin administered once daily for 3 days is as efficacious and well tolerated as co-amoxiclav given three times daily for 10 days in the domiciliary treatment of adults with acute lower respiratory tract infections. © 1996 The British Society for Antimicrobial Chemotherapy Articles nationallicence Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 93-101 0305-7453 37<93 1996 37 jac https://doi.org/10.1093/jac/37.suppl_C.93 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.suppl_C.93 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Gris P. Department of Pneumology/Physiology, Clinique Cesar de Paepe, Brussels, and Hopital Civil de Jumet, 6040 Jumet, Belgium NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37(1996-06), 93-101 0305-7453 37<93 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford